Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Long-Term Debt Repayments (2024 - 2025)

Indivior Pharmaceuticals has reported Long-Term Debt Repayments over the past 2 years, most recently at $5.0 million for Q4 2025.

  • Quarterly results put Long-Term Debt Repayments at $5.0 million for Q4 2025, down 97.9% from a year ago — trailing twelve months through Dec 2025 was $17.0 million (down 92.92% YoY), and the annual figure for FY2025 was $17.0 million, down 92.92%.
  • Long-Term Debt Repayments for Q4 2025 was $5.0 million at Indivior Pharmaceuticals, up from $4.0 million in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for INDV hit a ceiling of $238.0 million in Q4 2024 and a floor of $1.0 million in Q1 2024.